Revenue: DKK8 million for Q1 2025, primarily from the license and development agreement for Zegalogue with Novo Nordisk. Research and Development Expenses: DKK290 million, driven by the development of petrelintide and related trials. Sales and Marketing Expenses: DKK37 million, mainly for pre-commercial activities related to rare disease assets. General and Administrative Expenses: DKK65 million, reflecting organizational strengthening and investments in IT and patents. Net Financial Items: DKK70 million, primarily from interest income on market securities. Cash Position: DKK8.5 billion as of March 31, 2025, expected to increase to approximately DKK18 billion after receiving the USD1.4 billion up-front payment from Roche. Financial Guidance: Net operating expenses projected between DKK2 billion and DKK2.5 billion for 2025, excluding Roche transaction costs. Warning! GuruFocus has detected 5 Warning Signs with ZLDPF. Release Date: May 08, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Zealand Pharma AS (ZLDPF) has entered a transformative collaboration with Roche on petrelintide, including co-development and co-commercialization rights with a 50/50 profit sharing in the US and Europe. The company has a strong financial position, with a cash equivalent and marketable securities totaling DKK8.5 billion as of March 31, 2025, and expects to receive a USD1.4 billion up-front payment from Roche. Zealand Pharma AS (ZLDPF) has a differentiated mid-to-late-stage obesity pipeline, with a focus on amylin analogs, which have shown potential for effective weight management. The company has strengthened its organization by hiring key personnel, including a new Chief Scientific Officer and a medical advisor in obesity, to drive its research and development efforts. Zealand Pharma AS (ZLDPF) is committed to advancing its rare disease programs, with clear paths forward for its late-stage programs and ongoing efforts to secure partnerships. Negative Points The company faces geopolitical and market uncertainties, which could impact its operations and growth plans. There are challenges in ensuring patient adherence to weight management therapies, as many patients struggle to stay on current treatments due to side effects. Zealand Pharma AS (ZLDPF) is still in the early stages of its obesity market evolution, with only about 2% of eligible patients currently on pharmacotherapy. The company is awaiting an inspection classification upgrade of its third-party manufacturer's facility, which affects the resubmission of its dasiglucagon application. There is significant competition in the amylin analog space, with other companies developing similar therapies, which could impact Zealand Pharma AS (ZLDPF)'s market position. Story Continues Q & A Highlights Q: Can you elaborate on the early discussions with Roche regarding petrelintide and the potential outlicensing of glepaglutide? A: David Kendall, Chief Medical Officer: We will fully engage with Roche once the clearance period is completed. Early data from CT-388 shows significant effects at lower doses, and we aim to optimize tolerability and formulation. Eric Cox, Chief Commercial Officer: There is significant interest in partnering for glepaglutide, and discussions are progressing well, though no specific timeline is set for a deal. Q: How do you plan to address maintenance opportunities for weight management therapies? A: Adam Steensberg, CEO: Most companies focus on weight loss, but maintaining therapy is crucial for health outcomes. We believe petrelintide's profile, which makes patients feel full faster, can improve tolerability and adherence. We plan to discuss maintenance strategies further with Roche. Q: What are the top doses tested in the ZUPREME-2 trial for overweight obesity with type 2 diabetes? A: Adam Steensberg, CEO: The top doses in ZUPREME-2 will be similar to those in ZUPREME-1. We believe amylin analogs can provide similar weight loss in patients with type 2 diabetes as in those without, based on previous data. Q: What should we expect from the petrelintide Phase 2 readout next year? A: Adam Steensberg, CEO: The readout will include body composition measurements using MRI. We aim for a product demonstrating 15-20% weight loss in Phase 3. The slope of the weight loss curve and tolerability profile will be key indicators of success. Q: What is your vision for the future R&D pipeline in the cardiometabolic space? A: Adam Steensberg, CEO: We plan to significantly increase R&D investments and will provide more details at our Capital Markets Day in December. We are exploring opportunities in chronic inflammation and immunology, with a focus on differentiated therapies beyond weight loss. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Zealand Pharma AS (ZLDPF) Q1 2025 Earnings Call Highlights: Strategic Collaborations and ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...